Soligenix Reports Q1 Loss, $6M Cash, Explores Strategic Options After Lead Drug Failure
SNGX is trading near its 52-week low of $0.301 (3.2% above the low).
Summary
Soligenix announced its first quarter 2026 financial results, reporting a net loss of $2.8 million with no revenue. The company ended the quarter with approximately $6.0 million in cash, which is projected to provide a cash runway into the second quarter of 2027. This update follows the previously disclosed halt of its pivotal Phase 3 FLASH2 trial for HyBryte™ due to futility on April 28, 2026, a significant setback for the company's lead asset. Given the trial failure and prior going concern warning, the company stated it is evaluating all strategic options, including merger and acquisition opportunities. While the cash position offers a short-term lifeline, the explicit strategic review highlights the critical juncture the micro-cap company faces, making future M&A or restructuring a key watch item for investors.
At the time of this announcement, SNGX was trading at $0.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.30 to $6.23. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.